Moteur de recherche d’entreprises européennes
Financement de l’UE (5 994 030 €) : Effet de l’ALlopurinol en plus de l’hypothermie pour les lésions cérébrales hypoxiques-ischémiques sur les résultats neurocognitifs Hor01/01/2016 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Effet de l’ALlopurinol en plus de l’hypothermie pour les lésions cérébrales hypoxiques-ischémiques sur les résultats neurocognitifs
Neonatal hypoxic-ischemic encephalopathy (HIE) is a major cause of death or long-term disability in infants born at term in the western world, affecting about 1-4 per 1.000 life births and consequently about 5-20.000 infants per year in Europe. Hypothermic treatment became the only established therapy to improve outcome after perinatal hypoxic-ischemic insults. Despite hypothermia and neonatal intensive care, 45-50% of affected children die or suffer from long-term neurodevelopmental impairment. Additional neuroprotective interventions, beside hypothermia, are warranted to further improve their outcome. Allopurinol is a xanthine oxidase inhibitor and reduces the production of oxygen radicals and brain damage in experimental, animal, and early human studies of ischemia and reperfusion. This project aims to evaluate the efficacy and safety of allopurinol administered immediately after birth to near-term infants with HIE in addition to hypothermic treatment. Beyond this primary objective, the project will provide information on the effect of hypothermia on pharmacokinetics of drugs with a similar metabolism as allopurinol in neonates. Furthermore it will give the opportunity to further develop and validate biomarkers for neonatal brain injury using advanced magnetic resonance imaging, biochemistry, and electroencephalogramms, which will then be available for future studies testing neuroprotective interventions. Finally, this trial will extend our knowledge about incidence of and risk factors for perinatal asphyxia and HIE possibly enabling generation of more preventive strategies for the future.
| ACE PHARMACEUTICALS B.V. | 1 461 536 € |
| Azienda Sanitaria Universitaria Friuli Centrale | 0,00 € |
| EBERHARD KARLS UNIVERSITAET TUEBINGEN | 1 957 065 € |
| Fundacion para La Investigacion del Hospital Universitario La Fe de La Comunidad Valenciana | 270 027 € |
| HELSINGIN YLIOPISTO | 127 875 € |
| HUS-YHTYMA | 179 551 € |
| Katholieke Universiteit Leuven | 210 313 € |
| Medizinische Universitaet Wien | 136 384 € |
| Oslo Universitetssykehus HF | 207 489 € |
| Ostravska Univerzita | 395,89 € |
| TARTU ULIKOOL | 98 426 € |
| TECHNISCHE UNIVERSITAET DRESDEN | 171 756 € |
| Universidade do Porto | 143 842 € |
| Universita Degli Studi Di Udine | 203 433 € |
| UNIVERSITAETSKLINIKUM TUEBINGEN | 0,00 € |
| UNIVERSITAIR MEDISCH CENTRUM UTRECHT | 666 360 € |
| UNIVERSITAT ZURICH | 0,00 € |
| Uniwersytet Medyczny im Karola Marcinkowskiego w Poznaniu | 159 576 € |
https://cordis.europa.eu/project/id/667224
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.